Abstracts A15 work-related activities consisting of nurse, pharmacist, and/or patient medication dispensing, preparation, administration and/or storage. Projects consisted of time and cost differences related to 1) three proton pump inhibitor dosage forms and seven administration methods, and 2) seven recombinant human growth hormone administration methods/devices. Performance-based time data were then used to determine personnel/patient opportunity time and supply costs associated with different forms of medications and delivery devices. Simulations were developed and used to hold independent variables constant so only observed differences between medications and/ or device types could be assessed. Statistical and micro-economic cost analyses were conducted specific to each type of medication and/or device. RESULTS: Processes and results show two detailed examples as case studies of how simulation-based research may be used to assess health care processes at the micro level. The advantages of isolating processes of interest from the day-to-day complexity of patient care are demonstrated. Simulations may also represent an efficient assessment alternative of health care processes at the micro level with potential for projection to the macro level as compared to live, direct observation, cost-intensive, patient-centered care practice evaluations. CONCLUSIONS: Simulation-based time-and-motion and activity-based cost analyses allowed detailed micro-level time, workload, and supply evaluations that may be projected to the macro level. Professional schools' simulation laboratories offer appropriate settings for such studies. OBJECTIVES: Demonstrate a technique to characterize the economic burden of illness over time, correcting for censoring bias and controlling for difference in baseline characteristics between comparison groups. A sample of patients with diagnosis of disease A in 2004-2008 were extracted from MarketScan® databases and followed to death, disenrollment, or December 31, 2008 (cases). The first diagnosis date was the index date. Enrollees without disease A were extracted as controls. Their index dates were assigned based on the distribution of index dates of cases. METHODS: First, Kaplan-Meier estimates for the probability of remaining in the data were calculated by month and disease status. Failure event was death or disenrollment. Censoring event was termination of MarketScan contract or end of study period. Next, total health care costs were estimated using generalized linear models (GLM) on the subsample of survivors/enrollees in each month, controlling for disease status, patient demographic and clinical characteristics. Adjusted costs were calculated by month and disease status using the regression estimates and average characteristics. Estimated total costs during the whole follow-up period were the sum of probability of remaining in the data multiplied by regression-adjusted costs in each month. RESULTS: At the end of year 1, 40.5% of cases deceased or disenrolled from insurance compared to 13.6% of controls (p < 0.001); at the end of year 4 these figures were 76.4% and 30.5%, respectively (p < 0.001). GLM results indicated significantly higher cost among the group with disease A in each month during follow-up. The adjusted costs based on average characteristics was $86,592 for cases vs. $6,178 for controls in the first year and $151,077 vs. $21,890 in the first 4 years. CONCLUSIONS: In studies with variable-length follow-up, an estimator combining the survivor probability and regression-adjusted cost is more robust to censoring bias, and better depicts the economic burden of illness over time.
CONCEPTUAL PAPERS & RESEARCH ON METHODS -Databases & Management Methods

PMC8 THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES
Banahan III BF, Pace PF University of Mississippi, Oxford, MS, USA OBJECTIVES: Researchers frequently use claims data to create comorbidity measures. The objective of this project was to examine how the number of months of observation data and the type of claims data can affect identification of comorbidities. METHODS: Inpatient (IP) and outpatient (OT) claims data were used to identify comorbidities for beneficiaries enrolled in a state Medicaid program. Beneficiaries were included if they were enrolled for a continuous 24-month period between January 2002 and December 2004. Data were used to identify the first month in which an ICD-9 code appeared for each of the 17 comorbidities included in the Charlson Comorbidity Index. The D'Hoore scoring system was used to identify ICD-9 codes associated with each comorbidity. Results from the IP and OT claims were combined to create overall comorbidity measures. RESULTS: The study included a total of 618,337 unique patients. The OT claims could identify almost all comorbidities (low of 88.0% for myocardial infarctions, high of 99.5% for diabetes). IP claims were much less likely to identify comorbidities (low of 11.5% for connective tissue disease, high of 45.7% for myocardial infarction). At 12 months, less than half of the beneficiaries with comorbid events during the 24-month period had been identified for dementia (43.9%), cerobrovascular disease (45.6%), peripheral vascular disease (45.6%), and myocardial infarction (48.4%). In contrast, 78.1% of patients with diabetes events and 69.0% of patients with chronic pulmonary disease events had been identified at 12 months. CONCLUSIONS: The percentage of patients ascribed comorbidities will vary significantly depending on the number of observation months. Obviously, the incidence rate for new events/diagnoses contributes to the increase over time. However, researchers must be careful since some comorbidities may not be associated with frequent enough physician office visits to accurately detect existing comorbidities when the number of observation months is short.
PMC9
DATA SCAFFOLDING: A PRAGMATIC APPROACH TO STRUCTURING A LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, FACILITATE REVIEW AND SUPPORT ANALYSIS
Ogden K 1 , Hansen R 1 , Rattana S 2 , Neil N 1 1 ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA, 2 ICON Clinical Research, Lifecycle Sciences Group, Chicago, IL, USA OBJECTIVES: Clinical literature reviews, especially systematic reviews, require the management and evaluation of large amounts of bibliographic data. Although the methodology for performing reviews is well documented, few sources share practical guidance on how to electronically manage citation data in order to efficiently inventory, organize, and assess published material. Spreadsheet tools (e.g., Excel®) give researchers unparalleled freedom to manipulate a large volume of information culled from source databases (e.g., MEDLINE®); however, many researchers lack a blueprint for structuring their data to facilitate review. METHODS: We describe a process of erecting "data scaffolding" that is critical to transforming a literature review spreadsheet into an agile, manipulable source of information that can triage, sort, and report on materials retrieved for review. RESULTS: Using a sample of literature data pulled from PubMed®, we describe several ideas for adding key structural components to a spreadsheet of citations that bring flexibility and functionality to the processes of article review and analysis. In doing so, we also describe the hows and whys of spreadsheet design to facilitate literature review, such as the importance of the spreadsheet layout; the addition of flag fields to use medical subject headings or key words to easily sort, organize, identify/retrieve, navigate, and summarize citations; and ways of leveraging built-in spreadsheet features such as autofilters, freeze-panes, and subtotals that can greatly facilitate the inventory and management of large volumes of citation data to support literature reviews. CONCLUSIONS: In an era of increasing volumes of published literature and the proliferation of rigorous, formalized, systematic and non-systematic reviews, researchers must adapt to growing demands. Existing spreadsheet tools can be leveraged to effectively meet these demands, in ways that not only provide for greater efficiency but in ways that may result in enhanced research capabilities.
PMC10 RATIONALE AND DEVELOPMENT OF AN ONLINE DIRECTORY OF DATABASE PROFILES FOR PHARMACOEPIDEMIOLOGY, OUTCOMES, AND POPULATION RESEARCH
Kamani SA, Goehring Jr EL, Singh VP, Nguyen-Khoa BA, Kapasi AJ, Jones JK DGI, Inc., Arlington, VA, USA OBJECTIVES: Large epidemiology studies using population databases are in high demand in the current health care environment. Simultaneously, the number of health care databases available for research has risen considerably. Increasingly complex research questions require population researchers to be more aware of the availability and details of databases worldwide. To address this growing need, a web-based directory with detailed profiles of population research databases was developed. (1999) (2000) (2001) (2002) (2003) . Over a 20-month period, we convened an advisory board, re-branded the website, and updated content. A web development firm built the infrastructure of bridgetodata.org. Content was developed by assessing existing database profiles and performing extensive literature reviews. A database profile template was created with 75 common fields covering the following categories: population type, demographics, physician, drug, diagnosis, procedure, economic, validation, linkage, and administrative data. We received advisory board feedback at multiple stages, and database managers were contacted for listing authorization and content approval. A quality assurance process involved systematic review of each profile by the primary editor, DGI staff, and database managers. RESULTS: The site was launched in November 2009 with 50 database profiles from USA, Europe, and Asia. It features a web interface designed to perform database searches by field type and to allow side-by-side comparison of multiple databases. Limitations included a short timeline and budgetary constraints. CONCLUSIONS: Development of a webbased directory of population research database profiles will enable the identification of appropriate databases for pharmacoepidemiologic, economic, and health services research. Other applications may include serving as an educational tool and as a model for developing new health care databases.
PMC11 CAP DATABASE-PROVISION OF OUTPATIENT PROCEDURE DATA IN A UNIFIED, STANDARDIZED LANGUAGE
Endel G, Weisser A Head Association of the Austrian Social Insurance Companies, Vienna, Austria OBJECTIVES: Due to the heterogeneous health care environment in Austria, data about procedures performed in outpatient clinics, ambulatories and in the outpatient sector have not been collected in a standardized language. However, this data is crucial for planning processes and health services provision. Therefore, the Ministry of Health in collaboration with the Austrian Social Security and 3 of 9 Federal States initiated a pilot project to collect this data and make it available for evaluation and planning processes in a standardized language according to CAP (Catalog for ambulatory procedures). METHODS: The data will be transferred into a new database in two data streams to ensure data protection. Data about the patient containing sex, age and other characteristics will be sent in a pseudonomyzed way in one data stream. Another will contain data about the procedures according to CAP and information about contract physicians, outpatient clinics and ambulatories. RESULTS: The new database will offer information about what until now has been more or less a black spot. It will give information about procedures performed in the ambulatory and outpatient sector for all stakeholders participating in this pilot project. CONCLU-SIONS: Data about outpatient clinics and ambulatories have not been made accessible in one database for all participating stakeholders in a standardized language until now. The initiated pilot project and the database created therewith offer an opportunity to cover this lack of information.
CONCEPTUAL PAPERS & RESEARCH ON METHODS -Modeling Methods
PMC12 RULING OUT EXTENDLY DOMINATED OPTIONS USING AN ICER MATRIX
O'Day K, Meissner B, Bramley T Xcenda, Palm Harbor, FL, USA BACKGROUND: Incremental cost-effectiveness ratios (ICERs) represent the cost per unit of effectiveness of switching to a more costly and more effective option. In reporting results for cost-effectiveness (CE) analyses, options that are strictly dominated are ruled out and no ICERs should be reported. Additionally, some options may be ruled out by extended dominance (i.e., there is a linear combination of two options that dominates an option not otherwise excluded by strict dominance). In order to plot the CE efficiency frontier both strictly and extendedly dominated options must be excluded. Calculating strict dominance (e.g., in Excel) is straightforward. However calculating extended dominance is more complex. METHODS: We present a method to exclude extendedly dominated options using an ICER matrix. To form an ICER matrix all options are rank ordered by cost. For a CE analysis with N options, the ICER matrix is an N x N-1 sized table, where the first column represents the ICER from the least costly option to each more costly option, the second column represents the ICER from the second least costly option to each more costly option, etc.. Negative ICERs, representing strictly dominated options, are excluded from the table. Extended dominance is established by calculating whether the ICER for a non-strictly dominated option is greater than the ICER for at least one more costly option. If so, the option is rule out by extended dominance, otherwise not. We show how to perform the required calculations in Excel and how to graphically plot the CE efficiency frontier once all dominated and extendedly dominated options have been excluded. CONCLU-SIONS: Strictly dominated and extendedly dominated options must be ruled out in order to plot the CE efficiency frontier. The ICER matrix is a systematic method to rule out strictly and extendedly dominated options.
PMC13 THE COST-EFFECTIVENESS SENSITIVITY CURVE: QUANTIFYING THE EFFECT OF INDIVIDUAL PARAMETER UNCERTAINTY IN A PROBABILISTIC MODEL
O'Day K, Meissner B, Bramley T Xcenda, Palm Harbor, FL, USA BACKGROUND: The cost-effectiveness acceptability curve (CEAC) graphically depicts the joint uncertainty in a probabilistic model by transforming the incremental cost-effectiveness ratio into a net-benefit framework to represent the probability that a strategy is cost-effective over a range of willingness-to-pay (WTP) thresholds. By characterizing the joint distribution of costs and effects for all model parameters, the CEAC simplifies the presentation of uncertainty compared to deterministic one-way and multi-way sensitivity analyses and allows decision makers to identify the preferred strategy based on their WTP threshold. However, in some instances presenting only the joint uncertainty may be a limitation of the CEAC. METHODS: We propose a method to graphically present the uncertainty contributed by a single parameter within a probabilistic model called the cost-effectiveness sensitivity curve (CESC). Like the CEAC, the y-axis of the CESC represents the probability that a strategy is costeffective. However, instead of WTP, the x-axis represents a specified range of values for a single model parameter. The CESC is generated by varying the chosen parameter over the specified range of values and calculating the net-benefit at each value for each simulation based on the sampled values of the remaining model parameters without resampling (note: to effect the net-benefit transformation the CESC is based on a single WTP threshold). Computationally, the CESC requires an additional series of calculations for each simulation corresponding to the desired number of points on the curve. The advantage of the CESC is that it probabilistically describes the effect of uncertainty of a single model parameter on cost-effectiveness. This is particularly useful for ex-ante pricing decisions and for early phase go/no-go decisions based on an anticipated range of effectiveness. CONCLUSIONS: The CESC is a useful tool in specific decision making contexts for quantifying the contribution of a single model parameter to uncertainty within a probabilistic model.
PMC14
MEDICATION LABEL EVALUATION PROCESS MODEL: USING THE STRUCTURAL EQUATION MODELING APPROACH TO BETTER PREDICT PURCHASE INTENTION
Dwibedi N, Sansgiry S University of Houston, Houston, TX, USA OBJECTIVES: The objective of this study was to examine whether the Over-the-Counter Medication Label Evaluation Process Model (OTC-LEPM) or its modified version explained consumer's purchase intention better. METHODS: Data collected during an experimental field study was reanalyzed using structural equation modeling (SEM). Purchase intention with regard to three OTC medications for pain was evaluated using simulated product package labels for Acetaminophen, Ibuprofen and Aspirin. The experiment was conducted with consumers in the process of selecting an OTC product at local pharmacy stores. Endogenous variables were product knowledge, product evaluation, attitude-toward-product label and purchase intention. An additional endogenous variable ease of use was used in the modified OTC-LEPM. Demographics collected were analyzed using descriptive analysis in SPSS. AMOS v17 was used to conduct SEM and test whether OTC-LEPM or modified OTC-LEPM was the better model to explain the variables that predict purchase intention. RESULTS: A total of 336 consumers participated in the study. A chi-square value using the SEM approach for OTC-LEPM was 6262.390. The SEM for the modified OTC-LEPM indicated that iteration limit was reached (55000). Alternative model approach produced 3 models with slightly better chi-square value. A new model was built by combining alternative model approach and McFadden's Choice Process. This model produced an improved fit, producing a chi-square value of 4697 (df = 902, p < 0.0001). This model validated that knowledge significantly causes attitude towards product label which directly and indirectly via product evaluation causes purchase intention and these causal links were statistically significant. It indicated that only one exogenous variable age was statistically significant. CONCLUSIONS: The modified OTC-LEPM may not be the best model to analyze consumer's OTC medication purchase intention. Further research is needed to evaluate variables that can improve the understanding of consumer's purchase intention.
PMC15
SYNCHRONIZATION OF RANDOM NUMBER STREAMS GREATLY ENHANCES EFFICIENCY OF PROBABILISTIC MODELS
Smolen LJ, Klein RW Medical Decision Modeling Inc., Indianapolis, IN, USA The inclusion of probabilistic components in health care models requires the implementation of random number sampling. Many microsimulation models use a single simple random number generator without concern for its properties. This limits the modeler's ability to use the identical series of random numbers for alternative treatment strategies or among comparators. Synchronization of model results between treatment arms within a model run is difficult unless separate random streams are used for each source of variation. Synchronization of random number streams requires maintaining arrays of starting and current random number seeds. If each source of variation (e.g., times or probabilities of death and major events) has its own stream then the simulation of identical patients in all treatment arms is possible. By resetting the seed for each arm, the model results are impacted only by differences in model input point estimates (for first-order analyses) or differences in the specified distributions of sampled model inputs (for second-order analyses). The impact of random number sampling is thus maximally correlated between treatments, and the differences in the occurrences of events common to both simulations, e.g., natural death, are not artificially inflated due to random sampling. Given a sufficient number of replications, stochastic models usually produce stable results. This is because any further increase in the number of modeled replications will have minimal impact on the average-based model results. If the modeled result is the ratio of differences, such as an incremental cost effectiveness ratio (ICER), small differences in the denominator often drive the estimate, requiring a large number of replications. The allocation of common events, particularly natural death, to designated random streams minimizes the impact of random sampling on the model results. The number of model replications (and thus execution time) needed to produce stable ICERs may be reduced by as much as 90%.
PMC16
REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS
Aggarwal S 1 , White N 2 , Stevens CA 3 1 PAREXEL Consulting, Bethesda, MD, USA, 2 PAREXEL Consulting, Centreville, VA, USA, 3 PAREXEL Consulting, Waltham, MA, USA OBJECTIVES: The recently made coverage decisions by UK's NICE, Scotland's SMC and the allocation of $1.1Billion for comparative effectiveness research by the United States, are strong indicators of trends in pricing and reimbursement that are likely to be observed in the future. To gain an additional insight into these trends, we analyzed the cost effectiveness studies for the top ten highest selling drugs (∼$80-95B worldwide sales). METHODS: The Top 10 drugs were selected based on their worldwide sales. For this analysis, we segmented these drugs into categories as primary care, specialty, small molecules, biologics, therapy areas and availability of generic alternatives. We analyzed the cost effectiveness studies that were published in peer-reviewed journals. Search was conducted using generic names of the drugs and the phrase "cost effectiveness" in abstract of the published study. RESULTS: During 2003-2008, the number of published studies on "cost effectiveness" have increased by more than 30%. Almost half of the published studies belong to-Remicade, Plavix and Enbrel. There is a large
